AROMICS project Bermes at iMIG conference 2020
Bermes project will be present at the 15th Meeting of the International Mesothelioma Interest Group (iMig 2020) that will take place in Brisbane, Australia in March 2020.
This multidisciplinary meeting will bring together over 500 delegates from around the world, and feature the most up-to-date research, diverse topics of interest, and educational sessions with leading experts. The meeting will offer plenty of networking opportunities with leading scientists and researchers, friends and colleagues.
AROMICS and the project Bermes selected for Tech Tour Contest
AROMICS among the 175+ European innovative companies in the High-technology sectors that will present its advances to an international audience of investors, key corporates and innovation experts.
AROMICS and its project BERMES selected at 7th mRNA Health Conference
Dr. Carme Plasencia, CEO of Aromics presented on 11-12 November the progress of the BERMES Project funded by the European Union’s Horizon 2020 programme at the 7th International mRNA Health Conference.
The conference is the main destination for meetings for industry professionals and academics to explore the rapid advance of mRNA science and therapeutic and diagnostic applications, providing participants with a platform to establish contacts with potential collaborators on advances in mRNA technology and to attend scientific presentations by the most relevant experts in the field
WORKING DAY ON ASBESTOS AND ITS IMPACT ON HEALTH
On the 15th November 2019, the first scientific working session on asbestos and its consequences in health will take place. It is a scientific day aimed to discuss about different aspects of the diseases directly associated to the exposure to fibres of the mineral, nowadays considered as a first level carcinogenic material by the World.
Bermes Project launch its web site: www.bermesproject.eu
The new web site is designed as a comprehensive resource for investors, prospective corporate partners and the life science community to learn more about EU-funded Bermes project, the product pipeline, partnerships and innovative technology.
AROMICS receives Horizon 2020 SME instrument funding to develop a new therapy for malignant mesothelioma
BERMES, a proposal submitted by the Spanish biotechnology company AROMICS, has been selected to receive EU funding from H2020 SME Instrument Phase 2 topic. This grant represents the first big step forward for the company as it looks for bringing the first lead compound NAX035, closer to clinical application in cancer.
About SME Instrument at Horizon 2020 Research and Innovation Program: The SME Instrument is a EU funding scheme intended to support the SMEs’ innovation activities. Highly innovative SMEs with a clear commercial ambition and a potential for high growth and internationalisation are the prime target. Phase 2 of SME Instrument is focused on innovation and demonstration actions (prototyping, miniaturisation, scaling- up, design, performance verification, testing, development of pilot lines, etc.) and market replication. http://eshorizonte2020.es/
About AROMICS: Applied Research using Omic Sciences (AROMICS) is a biotechnology company founded in 2005 and located in the Barcelona Science Park. AROMICS is a focused on the development of novel therapies therapies and diagnostic products targeting and effective management of relevant human health diseases like cancer. http://www.aromics.es